======================================================== PAIN MANAGEMENT 2004 - Analysing Regulatory, Commercial & Pharmaceutical Practices 8th and 9th September 2004 (Workshop 7th September 2004) Marriott Kensington Hotel, London ======================================================== **FULL AGENDA BELOW** - PDF COPY OF THE BROCHURE NOW AVAILABLE Visiongain b2b Conferences is pleased to announce that 'Pain Management 2004 - Analysing Regulatory, Commercial & Pharmaceutical Practices ' will be run in early September this year. This event will follow up on the success of 'Future Pain Drugs 2003' but as a case-study based event will focus more on future targets and market development. The agenda is now complete, a list of confirmed speakers and topics can be found below. KEY THEMES: - Identify Key Market Segments and Profit From Emerging Trends in Pain Therapeutics - Clinical Models for Pain- Learn Which Will Suit Your Company Needs - Discover How Drug Delivery Systems will Shape the Future of Pain Therapeutics, Highlighting Lucrative Market Opportunities - Learn From the Best Practice Case Studies such as: Actiq- SPM 927- GPI 5693- Imitrax- Tramadol - Buprenorphine- Sativex - Examine the Key Legal and Regulatory Issues in the Development of Novel Pain Therpaeutics - Assess the Advances in Cannabis Based Medicines- R&D and Delivery Technologies - Advice on Scheduling of Centrally Acting Analgesics CONFIRMED SPEAKERS **Dr. Peter McIntyre, Lab Head/ Head of Exploratory Pain Projects, Novartis **Dr. Sharon Bingham, Somatic Pain - Pain Research, Neurology CEDD, GlaxoSmithKline **Gary Liversidge, Senior Director, Project Planning and Management, Elan **Praveen Anand, Professor Clinical Neurology, Imperial College **Dr. Stuart Bevan, Director, Novartis Institute for Medical Research **Dr. Jeffry Vaught, Senior Vice President & President, R&D Division, Cephalon **Dr. Christine Rauschkolb, Program Director/ Medical Scientist Pain, Schwarz Bioscience **Dr. Tony Ho, Associate Director, Merck **Dr Mike Reed, Director Branded Product Marketing International, Alpharma **Dr. Krystyna Wozniak, Lead Scientist on NAALADase program, Guilford Pharmaceuticals Inc **Dr. Stephen Wright, Director of R&D, GW Pharma Ltd **Dr. Francesco Impagnatiello, Pharmacologist- Pain Research, NicOx WHO SHOULD ATTEND -Medical Director -Divisional VP, Neurological & Urological -Pain, Migraine Research -Divisional VP, Immunosciences Development -Inflammatory Therapeutics -Respiratory RA Disease Group -Head of clinical development/ VP clinical development -Head of clinical research, CNS -Head of R&D (Pain/CNS/Depression) -CNS clinical project management -Head of CNS therapeutics -Chief Technical Officer -Director, Preclinical R&D -Vice President, Research -Vice President, Research and Development 2003's TESTIMONIALS "interesting topics, well organised" "excellent conference" "very good, covering a wide aspect of pain therapy" "topline overview of the field" "topical + scientifically sound" "exceeded expectations, high scientific level" --------------------- DELEGATE REGISTRATION --------------------- Places at this event are limited, please call or email me now to secure your place - PRICING - Attend the: ** Conf. + pre conf. workshop GBP 1600.00 Plus VAT ** Conference only Fee: GBP 1299.00 Plus VAT ** Pre conference workshop only Fee: GBP 650.00 Plus VAT - BOOKINGS - Booking is easy, simply contact Joe Stone on: Telephone: +44 (0)20 8767 6711 Fax: +44 (0)20 8767 5001 Email: mailto:joe.stone@visiongain.com Terms and conditions apply - see below. Kind regards, Joe Stone Account Manager Visiongain b2b Conferences Tel: +44 (0) 20 8767 6711 http://www.b2b-conferences.com mailto:Joe.stone@visiongain.com ============================================================================================== ----------------- ** FULL AGENDA ** ----------------- PRE-CONFERENCE INTERACTIVE WORKSHOP - Tuesday 7th September 2004 LifeSpan Biosciences: The Pathology of Pain Led by: Dr. Julian Beesley, VP European Sales & Business Development, LifeSpan Biosciences, Inc -Molecular pathology approach and studies at LifeSpan -Industrialization of the molecular pathology process -Drug targets, selection of targets and receptor localisation -Automated Lifespan Imaging and Analysis System (ALIAS) ===================================== Day One Wednesday 8 th September 2004 ===================================== 09:00 Registration and coffee 09:30 Opening remarks from the Chair MODELS AND TARGETS 09:40 Developments in Pain Therapy- Ventures for Your Company * Molecular targets in pain research- past, present and future * Research methodologies- how can you implement them? * Research tools and how best to use them * Balancing risk in the research portfolio - gain positive results for your company * Outlook: new targets for pain relief ligands and the future for pain therapies in the clinic Dr. Peter McIntyre Lab Head/ Head of Exploratory Pain Projects Novartis 10:20 Human Pain Models- How Can You Maximise Their Use? * Limitations of current animal models- find how they relate to human data * Clinical needs- pathophysiological and imaging surrogates * Lessons to learn from failed clinical trials- gain knowledge on avoiding and overcoming similar problems * How to increase the success of Phase II clinical trials * Target validation: novel pain targets in human chronic states * How to select patients for successful POC clinical trials * New models for assessing pain- examples and how to implement them Praveen Anand Professor Clinical Neurology Imperial College 11:00 Morning Coffee 11:20 How to Use Nitric Oxide (NO) Properties to Achieve Effective Therapeutics * NO-releasing analgesics: a novel class of drugs for the treatment of pain * The contribution of NO-releasing moiety to commonly-used analgesics: rationale and potential added values * Case studies: NO-releasing paracetamol/NO-releasing gabapentin * Potential mechanisms of action of NO in pain/inflammation Dr. Francesco Impagnatiello Pharmacologist- Pain Research NicOx 12:00 Find New Targets and Pointers to Validate them * Pain signalling pathways- where can you find new targets? * Pharmacological mechanisms of pain * Pain platforms- detailing the molecular basis * Target validation- strategies for success * Target identification vs target validation * Target treatment- is there a need and future ventures for your company Dr. Ray Scraggs Pharmaceutical Consultant visiongain Consultancy 12:40 Lunch 14:00 Using Animals- How to make them Disease Relevant Pain Models? * Classical versus novel approaches to pain models- what will suit your needs? * Changing views on behavioural versus functional endpoints * How you can validate a model- pointers * Difficulties in assessing pain in animals- how effective are these models and how to improve them * Screening putative analgesics * How to use animal models for causes of pain Dr. Sharon Bingham Somatic Pain - Pain Research Neurology CEDD GlaxoSmithKline 14:40 The Role of Vanilloid Receptors in Nociception * Expression of vanilloid receptors - how to demonstrate the existence of specific vanilloid receptors * Molecular and functional characterisation of cloned VR1 * VR1 as a pivotal transducer * Comparison of VR1 and native receptors- what advantaged can you make use of? Dr. Stuart Bevan Director Novartis Institute for Medical Research 15:20 Afternoon Tea 15:40 Advice on Scheduling of centrally acting analgesics * The rationale of scheduling- how and why? * International and national conventions and laws- what to foresee as a result * Development and registration of controlled drugs * Marketing of controlled drugs- recommendations * Case Studies: Tramadol and buprenorphine Dr. Franz Philipp Gerstheimer Corporate Medical and Scientific Services Grunenthal GmbH OVERCOMING CANCER PAIN 16:20 CASE STUDY: Actiq, the only FDA Approved Drug for Breakthrough Cancer Pain * Temporal characteristics of persistence and breakthrough pain * Actiq's novel oral transmucosal system- how does it work? * Parmacokinetics and pharmacodynamics of oral transmucosal fentanyl delivery * What are the benefits of oral transmucosal delivery? * Onset of action and duration of effect * Side effects and how you can overcome them Dr. Jeffry Vaught Senior Vice President & President, R&D Division Cephalon 17:00 Questions and Discussion 17:20 Summation of day one from conference chair ==================================== Day Two Thursday 9 th September 2004 ==================================== 09:00 Registration and Coffee 09:30 Opening remarks from the Chair NEUROPATHIC PAIN MARKET 09:40 CASE STUDY: Pharmacology of SPM 927 and its Relevance to Clinical Practice * Basic pharmacology of SPM 927 * Efficacy of SPM 927 in an animal model for diabetic neuropathy * Pharmacological profiling in further animal models for chronic pain- what can you impliment in practice? * This anti-convulsant drug's mechanism of action Dr. Bettina Beyreuther Senior Scientist Pharmacology- Preclinical Development Schwarz BioSciences 10:20 CASE STUDY: SPM 927 - A Novel Promising Pain Treatment * Human pharmacology of SPM 927 * 'First in patient' evaluation- where can improvements be made? * Efficacy and tolerability in diabetic neuropathy * Efficacy in other indications Dr. Christine Rauschkolb Program Director/ Medical Scientist Pain- Clinical Development Schwarz BioSciences 11:00 Morning Coffee 11:20 NAALADase Inhibition: a Novel Mechanism for Treating Neuropathic Pain and Peripheral Neuropathy * Selective Blockade of excitotoxic glutamate * Efficacy in multiple animal models of peripheral neuropathy, neuropathic pain, stroke, and ALS * Phase 1 trial results Krystyna Wozniak Lead Scientist on NAALADase Program Guilford Pharmaceutical Inc HEADACHE AND MIGRAINE PAIN- PRODUCT ANALYSIS VIOXX - First Coxib Approved of Acute Migraine * Migraine - a serious debilitating disorder * Current acute migraine therapy * Efficacy of rofecoxib in acute migraine therapy * Safety of rofecoxib in acute migraine therapy * Role of rofecoxib in acute migraine therapy Dr. Tony Ho Associate Director Merck 12:40 Lunch MARKET OPPORTUNITIES 14:00 CASE STUDY: The NanoCrystal Technology Approach * How to overcome solubility issues for pain therapeutics * Technology performance advantages * Can it be used as a life cycle management tool? * A commercialised, validated solution Gary Liversidge Senior Director, Project Planning and Management Elan 14:40 CASE STUDY: Peptrans, a Novel Approach to Brain Delivery * The BBB and drug delivery in the CNS * Pep:trans mechanism of action * Delivery of analgesics- an effective solution? * Potential within the market- where can you capture a share of the market? Jamal Temsamani Director, Preclinical R&D Synt:em 15:20 Afternoon Tea 15:40 Cannabis Based Medicines- How to Optimise Pain Treatment * Clinical indication and pain management with cannabinoids * GW cultivation license, possession and supply for medical research * R&D clinical trials- quality, safety, efficacy and phase I-III trials * Drug delivery technologies- oro mucosal sprays, oral formulations and inhalers * Limitations of cannabinoid therapies- where can you fail? * Case study: update on Sativex Dr. Stephen Wright Director of R&D GW Pharma Ltd 16:20 Regulatory Limitations- Use and Distribution of Narcotic Drugs * Medical narcotics, the potential for misuse * The prevention of drug abuse- new methods and control * National drug policies- updates and how to enforce them * Control of substances- how it limits availability for legitimate use Dr. Mike Reed Director Branded Product Marketing International Alpharma 17:00 Generics: Identifying and Overcoming the Legal and Regulatory Challenges of the Future * The latest developments affecting the generic drug sector and pharmaceutical legislation * Important legal issues- current scientific initiatives * Potential solutions to current challenges * Key regulatory issues in Europe Mr. Horst Kastrup VP Worldwide Regulatory Affairs Viatris 17:40 Questions and Discussion 18:00 Chairman summation 18:10 Close of Conference Terms & Conditions NB - Due to high demand, we do not 'reserve' or 'hold' places - a request for an invoice to be raised will be treated as an official booking and will be subject to the cancellation policy as outlined below. Cancellations/substitutions and name changes: All bookings carry a 50% liability after the booking has been made, by post fax, email or web. There will be no refunds for cancellations received on or after one month before the start of the conference (e.g. cancellation on or after 20th January for a conference starting on 20th February). If you decide to cancel after this date the full invoice remains payable. Conference notes, which are available on the day, will be sent to you. Unfortunately we are not able to transfer places between conferences and executive briefings. However if you are unable to attend the event you may make a substitution/name change at any time as long as we are informed in writing by e-mail, fax or post. Name changes and substitutions must be from the same company and are not transferable between companies or countries. Indemnity: visiongain Ltd reserve the right to change the conference/executive briefing content, timing, speakers or venue without notice. The event may be postponed or cancelled due to acts of terrorism, war, extreme weather conditions, industrial action, acts of God or any event beyond the control of visiongain Ltd. If such a situation arises we will endeavour to reschedule the event. However, visiongain Ltd cannot be held responsible for any cost, damage or expenses, which may be incurred by the customer as a consequence of the event being postponed or cancelled. We therefore strongly advise all customers to take out insurance to cover the cost of the registration, travel and expenses. To unsubscribe please reply with unsubscribe in the subject line. Data protection: Visiongain Ltd gathers and manages data in accordance with the Data Protection Act 1998. Information contained about you may be used to update you on visiongain Ltd products and services via post, telephone, fax or email, unless you state otherwise. If you wish your details to be amended, please send your request to the Database Manager, visiongain Ltd, 40 Tooting High Street, London, SW17 0RG. Alternatively please reply with unsubscribe in the subject line. Please allow approximately 7 days for your removal or update request, you may receive additional pieces of communication from visiongain Ltd during the transitional period, whilst the changes come into effect. ##################################################################################### This email has been scanned by MailMarshal, an email content filter. #####################################################################################